Tag: ORBITA

In some cases, we are not doing PCI in the right...

 “The real question is: who should get percutaneous coronary intervention (PCI)? I do not believe that we are doing too many PCIs but in...

EuroPCR 2018: FFR-guided PCI reduces spontaneous myocardial infarction

Five-year data from FAME (Fractional Flow Reserve vs. Angioplasty for Multivessel Evaluation) 2 show that patients with stable disease who undergo percutaneous coronary intervention...

EuroPCR 2018: New ORBITA analysis finds iFR/FFR values do not predict...

New data from the ORBITA trial indicates percutaneous coronary intervention (PCI) does not significantly reduce exercise time compared with a sham procedure in patients...

Justin Davies

Justin Davies (Imperial College London, London, UK) has always been interested in computer programming and science and has combined these two passions in his...

Cardiovascular News Issue 48—March 2018 US edition

In this edition of Cardiovascular News (issue 48, US edition), we report on the top stories from TCT 2017—including: ORBITA, CULPRIT-SHOCK and the cost-effectiveness data from...

Cardiovascular News Issue 48—March 2018

In this edition of Cardiovascular News (issue 48), we report on the top stories from TCT 2017—including: ORBITA, CULPRIT-SHOCK and the cost-effectiveness data from...

TCT 2017: FAME 2 provides support for PCI in stable disease...

Following ORBITA, which indicated percutaneous coronary intervention (PCI) did not provide benefit over a sham procedure in patients with stable coronary artery disease, the...

Interventional cardiology in the Twitterverse

The past few years has witnessed increasing clinician engagement with social media platforms, including Twitter (which, overall, has 300 million active users). Well-known “Tweeters”...

A bold new study could alter the orbit of elective PCI

The ORBITA (Objective randomised blinded investigation with optimal medical therapy of angioplasty in stable disease) study, recently presented at 2017 Transcatheter Cardiovascular Therapeutics (TCT)...

TCT 2017: Sham-controlled trial raises doubts about benefit of angiography-guided PCI...

ORBITA (Objective randomised blinded investigation with optimal medical therapy of angioplasty in stable disease)—the first-ever sham controlled trial of percutaneous coronary intervention (PCI)—indicates that...